Skip to main content

Avapag 20 mg ( Avatrombopag)

Introduction to Avapag 20 mg

Avapag 20 mg is identified as a medicine containing avatrombopag, an oral thrombopoietin receptor agonist (TPO-RA). This type of medicine stimulates platelet production in the bone marrow and may help increase platelet counts in patients with certain medical conditions.

Platelets are small blood components that help the body form clots and control bleeding. When platelet levels become too low, a condition known as thrombocytopenia can develop.

Avatrombopag is used in selected adults with thrombocytopenia associated with chronic liver disease who are scheduled to undergo a medical procedure, and adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.

Avapag’s product-specific manufacturer, regulatory authorization, formulation details and official prescribing instructions should be confirmed through its own packaging and documentation.

Product Information

Product detailInformation
Product nameAvapag
Stated strength20 mg
Active ingredientAvatrombopag
Medicine classThrombopoietin receptor agonist
AdministrationOral, subject to verified product instructions
Main therapeutic effectStimulates platelet production
Main treatment areasSelected cases of chronic liver disease-associated thrombocytopenia and chronic ITP
Prescription statusFollow applicable local prescription requirements

What Is Avatrombopag?

Avatrombopag is an orally administered small-molecule medicine that activates thrombopoietin receptors.

These receptors are involved in the development and maturation of megakaryocytes, which are large bone marrow cells responsible for producing platelets.

By stimulating these receptors, avatrombopag helps increase platelet production.

Unlike treatments that directly replace platelets, avatrombopag works by encouraging the body’s own platelet-producing process.

What Is Avapag 20 mg Used For?

The established adult treatment uses of reference avatrombopag tablets include the following conditions.

Chronic Liver Disease-Associated Thrombocytopenia

Some people with chronic liver disease develop low platelet counts.

This may be associated with changes in liver function, portal hypertension, splenic enlargement and reduced thrombopoietin production.

For selected adults with chronic liver disease-associated thrombocytopenia who are scheduled to undergo a medical procedure, avatrombopag may be prescribed to increase platelet counts before the procedure.

The treatment aims to reduce the need for platelet transfusions associated with the planned procedure.

Chronic Immune Thrombocytopenia

Chronic immune thrombocytopenia is an autoimmune disorder in which the immune system mistakenly targets platelets.

This can cause reduced platelet levels and increase the risk of bruising and bleeding.

For selected adults who have not responded adequately to previous treatment, avatrombopag may help increase platelet production.

The objective is to achieve a platelet count that reduces clinically important bleeding risk rather than to normalize platelet levels.

How Does Avapag Work?

Avatrombopag activates thrombopoietin receptors, also known as c-Mpl receptors, on platelet-producing cells in the bone marrow.

Its mechanism involves several stages:

  1. Avatrombopag is absorbed after oral administration.
  2. The medicine reaches the bone marrow.
  3. It activates thrombopoietin receptors.
  4. Receptor activation stimulates megakaryocyte development.
  5. Megakaryocytes mature and produce platelets.
  6. Platelet counts may increase over time.

The medicine stimulates platelet production rather than directly supplying platelets to the bloodstream.

For the reference tablet product, platelet counts may begin increasing within approximately 3–5 days, with peak increases generally occurring around 10–13 days. Individual responses can vary.

Potential Benefits of Avapag

When prescribed appropriately, avatrombopag may offer several treatment benefits.

Increased Platelet Production

Avatrombopag stimulates the bone marrow’s platelet-producing cells, potentially increasing platelet counts.

Oral Administration

Reference avatrombopag tablets are administered orally, providing a tablet-based treatment option.

Support Before Medical Procedures

In selected patients with chronic liver disease-associated thrombocytopenia, treatment may increase platelet counts before a scheduled procedure.

Treatment Option for Chronic ITP

For selected adults with chronic ITP who have not responded adequately to previous treatments, avatrombopag provides another therapeutic option.

Reduced Need for Platelet Transfusion

In the approved chronic liver disease treatment setting for the reference product, avatrombopag can reduce the proportion of patients requiring platelet transfusions or rescue procedures for bleeding.

Treatment benefits depend on the patient’s condition and individual response.

Avapag 20 mg Dosage Information

The appropriate avatrombopag dosage depends on the condition being treated, baseline platelet count and treatment response.

The reference tablet prescribing information provides different regimens for chronic ITP and chronic liver disease-associated thrombocytopenia.

Adult Chronic ITP

The reference adult ITP regimen begins with 20 mg once daily with food.

The dosage may be adjusted according to platelet-count response.

The maximum recommended adult dosage in the reference prescribing information is 40 mg per day.

Chronic Liver Disease-Associated Thrombocytopenia

For the reference tablet product, the treatment course before a scheduled procedure lasts five days.

Baseline platelet countReference daily dose
Below 40 × 10⁹/L60 mg
40 to below 50 × 10⁹/L40 mg

Treatment begins 10–13 days before the scheduled procedure, with the procedure generally performed 5–8 days after the final dose.

These are reference-product instructions and are not confirmation of an Avapag-specific dosage regimen.

Patients should follow the verified prescribing information for their actual medicine.

How to Take Avapag

The reference tablet product is taken orally with food.

General precautions include:

  • Follow the prescribed administration schedule.
  • Use the dose specified by your healthcare professional.
  • Do not take additional tablets without medical advice.
  • Do not independently change the treatment duration.
  • Follow the official instructions for missed doses.
  • Attend recommended platelet-count monitoring appointments.

Confirm the specific administration instructions for Avapag before use.

Possible Side Effects

Like other prescription medicines, avatrombopag may cause side effects.

Reported adverse reactions with reference-product avatrombopag include:

Reactions Reported in Chronic Liver Disease

  • Fever.
  • Abdominal pain.
  • Nausea.
  • Headache.
  • Fatigue.
  • Peripheral edema.

Reactions Reported in Chronic ITP

  • Headache.
  • Fatigue.
  • Bruising.
  • Nosebleeds.
  • Upper respiratory tract infections.
  • Joint pain.
  • Gum bleeding.
  • Petechiae.
  • Nasopharyngitis.

These reactions do not occur in every patient.

Contact your healthcare professional if side effects persist or become concerning.

Serious Safety Warnings

Thrombotic and Thromboembolic Complications

Avatrombopag treatment may be associated with an increased risk of blood clots.

Patients should seek urgent medical attention if they experience:

  • Sudden chest pain.
  • Shortness of breath.
  • Pain or swelling in one leg.
  • Sudden weakness or numbness.
  • Difficulty speaking.
  • Sudden changes in vision.

Excessive Platelet Counts

A platelet count that becomes too high may increase the risk of thrombotic complications.

The aim of treatment is to achieve an appropriate platelet response, not necessarily a normal platelet count.

Bleeding After Discontinuation

Patients with chronic ITP may experience a decrease in platelet counts after stopping treatment.

Follow-up monitoring may be necessary after treatment is discontinued.

Precautions Before Using Avapag

Before starting treatment, tell your doctor if you have:

  • A history of blood clots.
  • Chronic liver disease.
  • A clotting disorder.
  • Cardiovascular disease.
  • Previous serious bleeding.
  • Other significant medical conditions.
  • Pregnancy or breastfeeding considerations.

Also provide a complete list of your prescription medicines, nonprescription medicines, vitamins and supplements.

Drug Interactions

Avatrombopag exposure may be affected by medicines that influence CYP2C9 and CYP3A4 metabolic pathways.

Certain medicines may increase or decrease avatrombopag exposure.

Inform your healthcare professional about all medicines you currently use.

Do not independently start, stop or adjust medicines during treatment.

Pregnancy and Breastfeeding

Patients who are pregnant, planning pregnancy or breastfeeding should discuss avatrombopag treatment with their healthcare professional.

The reference product prescribing information warns of potential fetal harm.

The reference prescribing information also advises against breastfeeding during treatment.

Individual treatment decisions should be made with appropriate medical guidance.

Storage Information

Follow the storage conditions stated on the specific Avapag packaging.

General storage precautions include:

  • Keep the medicine away from children.
  • Store it according to the package instructions.
  • Check the expiry date before use.
  • Avoid using damaged or suspicious packaging.
  • Do not use expired tablets.
  • Keep the original packaging available for product identification.

Product Authenticity and Verification

Before using Avapag 20 mg, review its product documentation.

Important details to check include:

  • Product name.
  • Active ingredient.
  • Stated strength.
  • Manufacturer information.
  • Batch number.
  • Expiry date.
  • Storage instructions.
  • Relevant regulatory details.
  • Official package leaflet.

The manufacturer and regulatory authorization of Avapag should not be assumed from information about other avatrombopag brands.

Frequently Asked Questions About Avapag 20 mg

1. What is Avapag 20 mg?

Avapag 20 mg is identified as a product containing avatrombopag, a thrombopoietin receptor agonist that stimulates platelet production.

2. What is the active ingredient in Avapag?

The stated active ingredient is avatrombopag.

3. What is Avapag used for?

Its active ingredient has established uses in selected adults with chronic liver disease-associated thrombocytopenia before a scheduled procedure and chronic ITP after insufficient response to previous treatment.

4. How does Avapag work?

Avatrombopag activates thrombopoietin receptors in the bone marrow, stimulating the development of platelet-producing cells.

5. Is Avapag a chemotherapy medicine?

No. Avatrombopag is classified as a thrombopoietin receptor agonist, not a conventional chemotherapy medicine.

6. Does Avapag increase platelet counts?

Avatrombopag stimulates platelet production and may increase platelet counts in appropriately selected patients.

7. How long does avatrombopag take to work?

For the reference tablet product, platelet counts may begin increasing within approximately 3–5 days, with peak increases generally occurring around 10–13 days.

8. What are the common side effects?

Reported reactions include headache, fatigue, nausea, abdominal pain, bruising and other effects depending on the treatment indication.

9. Can Avapag cause blood clots?

Thrombotic and thromboembolic complications are important safety risks associated with avatrombopag.

10. Does Avapag require a prescription?

Follow the prescription requirements in your country and obtain medical assessment before using avatrombopag.

11. Can I take Avapag without platelet monitoring?

No. Platelet-count monitoring is an essential part of treatment with avatrombopag.

12. Who should avoid Avapag?

Suitability depends on individual medical circumstances, potential risks and the verified product information. A healthcare professional should determine whether treatment is appropriate.

Conclusion

Avapag 20 mg is identified as a product containing avatrombopag, an oral thrombopoietin receptor agonist that stimulates platelet production.

Its active ingredient has established uses in selected adults with chronic liver disease-associated thrombocytopenia before a scheduled procedure and chronic immune thrombocytopenia.

Correct treatment requires appropriate patient selection, verified product instructions, platelet-count monitoring and awareness of possible adverse reactions.

Patients should consult a qualified healthcare professional before starting or changing treatment.

Medical Disclaimer

This content is provided for general educational purposes only. It is not a substitute for professional medical advice, diagnosis or treatment.

The clinical information about avatrombopag is based on reference-product information and should not automatically be interpreted as verified product-specific information for Avapag.

Always confirm Avapag’s manufacturer, formulation, regulatory status and official prescribing instructions before use.